SYNCONA
A specialist investor which aims to found and build companies in areas of 'critical' health.
SELL
126p
BUY
127.6p
CHARGE PER TRADE
£4.95
TODAY'S CHANGE
0.00%
OCF
1.14%
YIELD
0%
1 YEAR
-26.74%Prices as at 04 Dec 2023.
Fund commentary last updated 29 Nov 2022.
Past performance is not an indication of future performance.
Capital at risk.
The investment objective is to deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes. The Company will target an IRR per share across its investment portfolio of 15% p.a. over the long term. Over time, it is intended that the Company should invest the significant majority of its assets in Life Science Investments.
Fund summary
| Sector | Biotechnology & Healthcare |
|---|---|
| Structure | INVESTMENT COMPANY |
| Launched | October 2012 |
| Size | £858m |
| Yield | 0% |
| Dividends paid | June, July, August |
Charges
| Annual Management Charge | 1.05% |
|---|---|
| Ongoing Charges Figure | 1.14% |
Investment Process
The information on this website is not intended to be advice or a recommendation to buy, sell or hold any investment mentioned. The value of investments and the income from them can go down as well as up and you may not get back the amount invested.
Past performance is not a guide to future performance. View full risk warning